Litcius/Paper detail

Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)

Nicola Silvestris, Oronzo Brunetti, Alessandro Bittoni, Ivana Cataldo, Domenico Corsi, Stefano Crippa, Mirko D’Onofrio, Michele Fiore, Elisa Giommoni, Michèle Milella, Raffaele Pezzilli, Enrico Vasile, Michele Reni

2020Cancers32 citationsDOIOpen Access PDF

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.

Topics & Concepts

MedicinePancreatic cancerLife expectancyInternal medicinePancreatic ductal adenocarcinomaClinical OncologyClinical PracticeOncologyAdenocarcinomaCancerGeneral surgeryFamily medicineEnvironmental healthPopulationPancreatic and Hepatic Oncology ResearchGastric Cancer Management and OutcomesCancer Genomics and Diagnostics
Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM) | Litcius